In a news release, Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) announced that "it has entered into a sponsored research agreement and an exclusive option to license agreement with North Carolina State University to develop a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform developed by Dr. Gavin Williams, Professor and Researcher at NC State."
The company explained that the platform Dr. Williams created "provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli."
Revive Therapeutics noted that it is presently seeking ways to scale production and market its own pharmaceutical-grade psilocybin. The firm has developed an oral thin film psilocybin-based product together with the University of Wisconsin-Madison using PharmaTher Inc.'s (PHRM:CSE, PHRRF:OTCQB) intellectual property and psilocybin research.
Revive Therapeutics CEO Michael Frank commented, "We are excited to partner with NC State and work with Dr. Williams and his team to develop a proprietary form of psilocybin that can be produced at scale for research and commercial purposes while allowing us to create our own unique product offerings with psilocybin in different delivery methods so as to treat the various mental health conditions and other diseases for which psilocybin has shown to be a potential viable treatment option...We continue to expand our psychedelic pharmaceutical objectives in specializing in novel products and uses of psilocybin for unmet medical needs."
The firm noted that Dr. Williams is a "decorated chemist and well known for his innovative work in polyketide biosynthesis," and that together with his team, Professor Williams recently developed an artificial enzymatic platform called the 'Alcohol Dependent Hemiterpene' (ADH) pathway for construction of alkyl pyrophosphates. Revive stated that the products biosynthesized in the ADH pathway will serve to form the basis for psilocybin and its derivatives with the objective of engineering E. coli to be a factory for psilocybin production.
Read what other experts are saying about:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.